相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments
Tamara Dangouloff et al.
ORPHANET JOURNAL OF RARE DISEASES (2021)
Natural history of Type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study
Melanie Annoussamy et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2021)
Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy
Deepa Chand et al.
JOURNAL OF HEPATOLOGY (2021)
Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study
Stacy A. Rudnicki et al.
NEUROTHERAPEUTICS (2021)
Risdiplam in Type 1 Spinal Muscular Atrophy
Giovanni Baranello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Thrombotic Microangiopathy Following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series
Deepa H. Chand et al.
JOURNAL OF PEDIATRICS (2021)
Limited Assessment of Respiratory Muscle Response to Nusinersen Treatment in Infants with Spinal Muscular Atrophy Reply
Antonella LoMauro et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)
244th ENMC international workshop: Newborn screening in spinal muscular atrophy May 10-12, 2019, Hoofdorp, The Netherlands
Tamara Dangouloff et al.
NEUROMUSCULAR DISORDERS (2020)
Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen
Karolina Aragon-Gawinska et al.
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY (2020)
New treatments in spinal muscular atrophy: an overview of currently available data
Sithara Ramdas et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
Drosophila SMN2 minigene reporter model identifies moxifloxacin as a candidate therapy for SMA
Piotr Konieczny et al.
FASEB JOURNAL (2020)
Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy
Haiyan Zhou et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2020)
Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study
Tim Hagenacker et al.
LANCET NEUROLOGY (2020)
European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy
Janbernd Kirschner et al.
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2020)
The Small-Molecule Flunarizine in Spinal Muscular Atrophy Patient Fibroblasts Impacts on the Gemin Components of the SMN Complex and TDP43, an RNA-Binding Protein Relevant to Motor Neuron Diseases
Delphine Sapaly et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2020)
Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps
Teresa Gidaro et al.
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY (2019)
Newborn screening for SMA in Southern Belgium
Francois Boemer et al.
NEUROMUSCULAR DISORDERS (2019)
Systemic nature of spinal muscular atrophy revealed by studying insurance claims
Scott L. Lipnick et al.
PLOS ONE (2019)
Salbutamol modifies the neuromuscular junction in a mouse model of ColQ myasthenic syndrome
Grace M. McMacken et al.
HUMAN MOLECULAR GENETICS (2019)
NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice
Laura Torres-Benito et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2019)
Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data
Marika Pane et al.
ANNALS OF NEUROLOGY (2019)
Discrepancy in redetermination of SMN2 copy numbers in children with SMA
David Christof Schorling et al.
NEUROLOGY (2019)
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
Darryl C. De Vivo et al.
NEUROMUSCULAR DISORDERS (2019)
Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment
Daniel M. Ramos et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Clinical Evidence Supporting Early Treatment Of Patients With Spinal Muscular Atrophy: Current Perspectives
Tamara Dangouloff et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2019)
Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol
Francesco Danilo Tiziano et al.
JOURNAL OF MEDICAL GENETICS (2019)
A SMN2 Splicing Modifier Rescues the Disease Phenotypes in an In Vitro Human Spinal Muscular Atrophy Model
Ye Seul Son et al.
STEM CELLS AND DEVELOPMENT (2019)
Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy
Kimberly K. Long et al.
HUMAN MOLECULAR GENETICS (2019)
One Year of Newborn Screening for SMA - Results of a German Pilot Project
Katharina Vill et al.
JOURNAL OF NEUROMUSCULAR DISEASES (2019)
The role of survival motor neuron protein (SMN) in protein homeostasis
Helena Chaytow et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2018)
Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN
Christian Hinderer et al.
HUMAN GENE THERAPY (2018)
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
E. Mercuri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Small-molecule flunarizine increases SMN protein in nuclear Cajal bodies and motor function in a mouse model of spinal muscular atrophy
Delphine Sapaly et al.
SCIENTIFIC REPORTS (2018)
Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 (SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)
Hasane Ratni et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Nusinersen in patients older than 7 months with spinal muscular atrophy type 1 A cohort study
Karolina Aragon-Gawinska et al.
NEUROLOGY (2018)
Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: Baseline data NatHis-SMA study
Aurelie Chabanon et al.
PLOS ONE (2018)
Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial)
Marloes Stam et al.
BMJ OPEN (2018)
MYOSTATIN INHIBITOR ACE-031 TREATMENT OF AMBULATORY BOYS WITH DUCHENNE MUSCULAR DYSTROPHY: RESULTS OF A RANDOMIZED, PLACEBO- CONTROLLED CLINICAL TRIAL
Craig Campbell et al.
MUSCLE & NERVE (2017)
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
J. R. Mendell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
R. S. Finkel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches
Virginie Mariot et al.
NATURE COMMUNICATIONS (2017)
Reloading Promotes Recovery of Disuse Muscle Loss by Inhibiting TGF Pathway Activation in Rats After Hind Limb Suspension
Jinyue Wang et al.
AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION (2017)
Securinine enhances SMN2 exon 7 inclusion in spinal muscular atrophy cells
Yu-Chia Chen et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
The Power of Human Protective Modifiers: PLS3 and CORO1C Unravel Impaired Endocytosis in Spinal Muscular Atrophy and Rescue SMA Phenotype
Seyyedmohsen Hosseinibarkooie et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2016)
Vascular Defects and Spinal Cord Hypoxia in Spinal Muscular Atrophy
Eilidh Somers et al.
ANNALS OF NEUROLOGY (2016)
Spinal Muscular Atrophy: More than a Disease of Motor Neurons?
L. A. Nash et al.
CURRENT MOLECULAR MEDICINE (2016)
Optimization of Morpholino Antisense Oligonucleotides Targeting the Intronic Repressor Element1 in Spinal Muscular Atrophy
Erkan Y. Osman et al.
MOLECULAR THERAPY (2016)
Amifampridine phosphate (Firdapse®) is effective and safe in a phase 3 clinical trial in LEMS
Shin J. Oh et al.
MUSCLE & NERVE (2016)
Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting
Rosamund C. Smith et al.
MOLECULAR CANCER THERAPEUTICS (2015)
A Phase 1/2a Follistatin Gene Therapy Trial for Becker Muscular Dystrophy
Jerry R. Mendell et al.
MOLECULAR THERAPY (2015)
SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice
James Palacino et al.
NATURE CHEMICAL BIOLOGY (2015)
Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial
Clemens Becker et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice
Esther Latres et al.
SKELETAL MUSCLE (2015)
Upper Limb Evaluation and One-Year Follow Up of Non-Ambulant Patients with Spinal Muscular Atrophy: An Observational Multicenter Trial
Andreea Mihaela Seferian et al.
PLOS ONE (2015)
The Small-Molecule Fast Skeletal Troponin Activator, CK-2127107, Improves Exercise Tolerance in a Rat Model of Heart Failure
Darren T. Hwee et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Treatment of sporadic inclusion body myositis with bimagrumab
Anthony A. Amato et al.
NEUROLOGY (2014)
SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy
Nikolai A. Naryshkin et al.
SCIENCE (2014)
Spinal Muscular Atrophy: New Findings for an Old Pathology
Daniele Bottai et al.
BRAIN PATHOLOGY (2013)
At the “Junction” of Spinal Muscular Atrophy Pathogenesis: The Role of Neuromuscular Junction Dysfunction in SMA Disease Progression
B. Goulet et al.
CURRENT MOLECULAR MEDICINE (2013)
Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival
Xiaolan Zhou et al.
CELL (2010)
Arrhythmia and cardiac defects are a feature of spinal muscular atrophy model mice
Christopher R. Heier et al.
HUMAN MOLECULAR GENETICS (2010)
Review: Neuromuscular synaptic vulnerability in motor neurone disease: amyotrophic lateral sclerosis and spinal muscular atrophy
L. M. Murray et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2010)
The Developmental Pattern of Myotubes in Spinal Muscular Atrophy Indicates Prenatal Delay of Muscle Maturation
Rebeca Martinez-Hernandez et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2009)
A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy
Kathryn R. Wagner et al.
ANNALS OF NEUROLOGY (2008)
A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs
Dana S. Mosher et al.
PLOS GENETICS (2007)
Brief report -: Myostatin mutation associated with gross muscle hypertrophy in a child
M Schuelke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
分享论文
